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Summary This study aims to determine the levels of Nε-(carboxymethyl)lysine (CML) in
patients with Type 2 diabetic patients with and without ischemic heart disease (IHD) and to
find for a possible association between circulating CML and a number of clinical parameters
including lipids, hemoglobin A1c (HbA1c) and malondialdehyde (MDA) in Type 2 diabetic
IHD patients. Serum CML levels were measured by enzyme-linked immunosorbent assay
using polyclonal anti-CML antibodies. Serum levels of CML and MDA were assessed in 60
IHD patients with Type 2 diabetes, 43 IHD patients without Type 2 diabetes, 64 Type 2
diabetics without IHD, and 80 sex- and age-matched healthy subjects. Correlations studies
between CML levels and lipids, HbA1c, and lipid peroxidation were performed in Type 2
diabetes patients with and without IHD. A statistical significance was observed in the levels of
serum glucose, lipids (triglyceride, total cholesterol, HDL-cholesterol), MDA, HbA1c, CML
and LDL-cholesterol (p<0.05) between the groups of the study. CML levels were significantly
increased in diabetic IHD patients compared with Type 2 diabetes patients but without IHD
(537.1 ± 86.1 vs 449.7 ± 54.9,  p<0.001). A positive correlation was observed between serum
levels of CML and MDA, r = 0.338 (p = 0.008) in Type 2 diabetes patients with IHD. However,
age, HbA1c and lipids had no significant influence on CML levels among diabetics (p>0.05).
In conclusion, this study demonstrates the effect of both diabetes and oxidative stress on the
higher levels of circulating CML. These results showed that increased serum levels of CML
are associated with the development of IHD in Type 2 diabetes mellitus.
Key Words: advanced glycation end products, Nε-(carboxymethyl)lysine, Type 2 diabetes mellitus,
ischemic heart disease, oxidative stress
Introduction
Diabetes mellitus (DM) represents a range of metabolic
disorders characterized by hyperglycaemia resulting from
insulin deficiency or insulin resistance or both. However,
it is well known established that in diabetes, long-term
complications ensue from abnormal regulation of glucose
metabolism. Type 2 (non-insulin dependent) diabetes mellitus,
the most prevalent form of the disease, is associated with
chronic macrovascular and microvascular complications and
it imposes a significant burden for both the diabetic population
and the health system. In macrovasculature, for example,
diabetes-accelerated atherosclerosis leads to the development
of heart attacks and stroke [1, 2]. In fact, all manifestations
of cardiovascular disease, coronary heart disease (CHD),
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stroke and peripheral vascular disease are substantially more
common in patients with Type 2 diabetes than in non-
diabetic individuals [3, 4]. Patients with Type 2 (non-insulin
dependent) diabetes mellitus (NIDDM) have a two- to
fourfold increased risk of fatal and non-fatal coronary events
[5]. CHD, another term given to ischemic heart disease (IHD),
can ultimately lead to heart attack. However, the most common
cause of death among individuals with diabetes mellitus is
ischemic heart disease [6]. Hyperglycaemia, the primary
clinical manifestation of diabetes, is strongly associated with
development of the diabetic complications [7].
Chronic hyperglycemia results in short-term metabolic
changes in lipid and protein metabolism and long-term
irreversible vascular and connective tissue changes. These
changes include diabetes-specific complications such as retino-
pathy, nephropathy and neuropathy and complications of the
macrovasculature such as atherosclerosis [8]. Hyperglycemia
drives non-enzymatic glycation and oxidation of proteins and
lipids leading to enhancement the formation of advanced
glycation end products (AGEs), which may be involved in the
pathogenesis of diabetic vascular diseases. Recently, it has been
documented that, among various factors, advanced glycation
end products (AGEs), a heterogeneous group of irreversibly
modified products formed in excess during aging and diabetes
mellitus, play a crucial role in this process [9]. It has been
reported that the process of AGE formation is accelerated by
hyperglycemia [10, 11]. When accelerated by hyperglycemia,
AGE accumulation is believed to contribute to the gradual
development of diabetic complications. Accumulation of
AGEs with structural alterations result in altered tissue
properties that contribute to the reduced susceptibility to
catabolism [9, 12]. Several interrelations have been shown
between oxidative stress and AGEs. Reactive oxygen
species generated in oxidative stress can in turn accelerate
the AGE formation. Yan et al. [13] showed that interaction
of AGEs with endothelial cells leads to oxidative stress by a
receptor-mediated process. Therefore, new definition arose,
such as glycoxidation which has been proposed by Baynes
[14], which refers to AGE formation through an oxidative
pathway.
Several advanced glycation end products structures have
been structurally identified including Nε-(carboxymethyl)
lysine (CML) [15, 16], Nε-(carboxyethyl)lysine (CEL) [17],
crossline [18], pentosidine [19], pyrraline [20], and imida-
zolone [21]. The two most commonly measured AGEs are
CML and pentosidine, which are glycoxidation products,
formed by sequential glycation and oxidation reactions
[22]. CML modification of proteins is one of the major
glycoxidation products formed in vitro by the reaction
between glucose and protein [16]. Schleicher and co-workers
[23] have shown by immunohistochemistry and chemical
analysis that CML was found in atheromas. Furthermore, it
is established that oxidation plays an important role in CML
formation [24]. CML, a well-characterized and major AGE
structure, is known to be a product of both lipoxidation and
glycoxidation [25]. Several in vitro experimental studies
demonstrated that CML [26] is a major antigenic AGE
structure  in vivo and it seems to be generated through
oxidative cleavage of Amadori products, cleavage of Schiff
base and autoxidation of glucose. Among these, oxidative
cleavage of Amadori products into CML is considered a
major pathway in vivo. Because CML is a major product of
oxidative modification of glycated proteins, it has been
suggested to represent a general marker of oxidative stress
and long-term damage of proteins in aging, atherosclerosis
and diabetes [27].
As the global prevalence of diabetes increases, laboratory
findings will continue to play a major role in the early
diagnosis and subsequently better management of the
diabetic vascular complications specifically ischemic heart
disease. The aim of the study was to investigate the serum
levels of CML in the IHD patients with and without Type 2
diabetes. Correlation between CML values with other clinical
parameters including lipid profile tests, lipid peroxidation in
term of malondialdehyde (MDA) and glycated hemoglobin
A1c (HbA1c) were examined.
Methods
Study population
The study was performed on 60 patients with both Type 2
diabetes and IHD aged (43.7 ± 14.9 years), 43 patients with
IHD but without Type 2 diabetes aged (48.4 ± 18.1 years),
and 64 diabetics without IHD aged (45.2 ± 17.1 years).
Smokers and former smokers were excluded from the study
and none of the patients had retinopathy or nephropathy or
other complications of diabetes. Subjects of age≥70 years,
known hepatic diseases, antioxidants medications, or insulin
therapy were also excluded from this study. Furthermore,
premenopausal women were not included since estrogens
affect plasma lipids and susceptibility of LDL to oxidation
[28]. Patient’s age, blood pressure and diabetes duration
were recorded. Healthy control subjects included in the
present study consisted of 80 healthy controls aged
44.0 ± 14.0 years. The age- and sex-matched healthy control
subjects were recruited from Klang Valley, Kuala Lumpur
by the distribution of questionnaires. Samples were also
collected from government bodies such as Police Force and
from private centres in Kuala Lumpur. All the healthy
control subjects were not diabetic and not on lipid lowering
drugs. In addition, those individuals were free from any
vascular diseases or even any increase in glucose levels or
both. The exclusion criteria for patients were also applied for
control group.
A 10 ml blood sample was collected from each participant
in two tubes, 5 ml in EDTA (1 mg/ml) tube and 5 ml in anti-CML and Ischemic Heart Disease in Type 2 Diabetes
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coagulant-free tube. Of the 5 ml EDTA anticoagulated
blood, 1 ml was kept for HbA1c analysis. Blood samples were
centrifuged at 3000 g for 15 minutes at room temperature
within 90 min after collection and the supernatant was stored
at  −80°C for MDA assay and −20°C for other assays
[29]. The blood samples were taken in the morning between
8:00 and 9:00 a.m. after an overnight (12–14 hours) fast
from each patient regularly attending the Cardiology and
Endocrinology Clinics at the University of Malaya Medical
Centre and from healthy control subjects. Written informed
consent was obtained from all patients and control subjects
prior to their inclusion in the study. The study was
performed in accordance to the approval by the Faculty
Perubatan University Malaya Medical Ethics Committee
(FPUM MEC). The experimental protocol for anti-sera
preparation was approved by the local ethics committee
for animal experimentation in the Faculty of Medicine,
University of Malaya.
Events definitions
Type 2 diabetes mellitus was defined according to World
Health Organization diagnostic criteria [30]. The procedures
used for evaluation of ischemic heart disease were previously
described [31, 32]. Briefly, the clinical diagnosis of angina
was based on a characteristic complaint of chest discomfort
or chest pain occurring on exertion and relieved by rest.
Confirmation was obtained by observing reversible ischemic
changes on electrocardiograms (ECGs) during an attack
or by giving a test dose of sublingual nitroglycerin that
characteristically relieves the pain in 1 to 3 minutes.
Preparation and characterization of CML- and CEL-
modified proteins
CML-bovine serum albumin (CML-BSA) and CML-
hemoglobin (CML-Hb) were prepared as described previously
[16, 26]. CEL-BSA and CEL-Hb were prepared according
to the method of Ahmed et al. [17]. The preparations were
dialyzed in phosphate buffer saline (PBS), pH 7.4 and filter
sterilized by passing through 0.45-µm filters and protein
concentrations were measured by the Bradford method [33].
CML- and CEL-modified proteins were characterized by
agarose gel electrophoresis [34] using 0.1 M Tris and
0.038 M glycine buffer (pH 8.7). The degree of modification
of lysine residues was quantitatively monitored by the
trinitrobenzenesulfonic acid (TNBS) assay as previously
described [35].
Production of polyclonal anti-CML antibodies
For preparation of polyclonal antibody against CML,
CML-BSA (0.5 mg/ml) prepared as above was emulsified in
an equal volume of 50% Freund’s complete adjuvant in total
volume of 2 ml and injected intramuscularly into multiple
sites in female New Zealand white rabbit (2.5 kg weight).
This procedure was repeated at weekly intervals for 3 weeks.
After a 2-week pause, the rabbit was received a booster
injection with the same amount of immunogen emulsified in
an equal volume of 50% Freund’s incomplete adjuvant [36].
The presence of antibodies was monitored by Ouchterlony
double diffusion in 1.0% agarose in PBS (pH 7.4). The anti-
serum showed a single precipitin line with CML-BSA upon
a double immunoprecipitation analysis. The rabbit was then
bled on the tenth day after the last booster injection and
antiserum was obtained to be used in the enzyme-linked
immunosorbent assay (ELISA) work.
Antiserum titer was determined by means of non-
competitive ELISA using CML-BSA as coating antigen.
Antiserum titer was defined as the serum dilution giving a
50% maximum absorbance (405 nm) signal employing
horseradish peroxidase (HRP)-conjugated anti-rabbit IgG as
secondary antibody [37]. The cross-reactivity of polyclonal
anti-CML antiserum with several proteins (CEL-BSA, CEL-
Hb, BSA, Hb) and competitors (CML-BSA, CML-Hb) was
evaluated by competitive ELISA at room temperature.
CML-BSA (used as adsorbed ligand antigen) and the
proteins and competitors diluted with buffer B (0.02%
Tween 20/PBS) into different concentrations (0.250, 0.500,
1.0, 5.0, 20, 50, 100 and 250 µg/ml), were used in the
experiment. Each well of an immunoplate was incubated
with 100 µl of CML-BSA (1.0 µg/ml) in 50 mM carbonate
buffer (pH 9.6) at room temperature for 1 h. The wells were
washed three times with buffer A (0.05% Tween 20/PBS)
and blocked with 100 µl of 6% skimmed milk in PBS for 1 h
with shaking followed by triple washing as above. Each
protein or competitor to be tested (60 µl) was mixed with
60 µl of antiserum (final dilution 1:2000) for 1 h and the
mixture (100 µl) was added to the wells of the mictotiter
plate followed by shaking for 1 h. The wells were washed
again, and then 100 µl HRP-conjugated anti-rabbit IgG
(0.1 µg/ml) was added to each well. After incubation for
1 h at room temperature, the wells were washed and
color was developed after incubation with 50 µl substrate
solution containing. 2,2'-azino-bis[3-ethylbenzthiazoline-6-
sulfonic acid (ABTS). The wells were incubated for 20–
30 min at room temperature in the dark followed by addition
of 100 µl of 1.0 N H2SO4 to stop the reaction. The
absorbance at 405 nm was read using an ELISA reader
(MRX Microplate Reader, Dynatech Laboratories Ltd, UK).
CML measurement by competitive ELISA
CML in the serum of the patients and healthy control
subjects were measured by competitive ELISA as described
above except that after incubation of the wells with the
blocking solution (6% skimmed milk), 60 µl serum to be
tested or CML-BSA standard with serial dilutions (0.100,
0.250, 0.500, 0.750, 1.0, 2.5, 5.0 and 7.5 µg/ml) were mixed
with an equal volume of antiserum (final dilution 1:2000)K.A. Ahmed et al.
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for 1 h and the mixture (100 µl) was added to the wells and
the mictotiter plate was shaken for 1 h. The remaining steps
were performed in the same manner to that described above
and the CML concentrations in the samples were determined
from the standard curve. The CML concentration was
expressed as ng CML/ml. All ELISA work was performed in
duplicates.
Detection of malondialdehyde
The amount of plasma malondialdehyde (MDA), an index
of lipid peroxidation, was determined by the thiobarbituric
acid reactive substances (TBARS) method as described by
Ohkawa et al. [38]. Briefly, 100 µl plasma or standard was
combined with an equal volume of 8.1% sodium dodecyl
sulfate. Then, 2.5 ml TBA/buffer (prepared by dissolving of
0.53% thiobarbituric acid in 20% acetic acid as adjusted to
pH 3.5 with NaOH) were added to the reaction mixture. The
tubes were covered with caps and incubated at 95°C for
60 min. The reaction was stopped by placing tubes on ice
followed by centrifugation at 4000 rpm for 10 min. The
optical density of pink color developed in the supernatant
was measured against distilled water as blank at 532 nm.
The measurements were performed in duplicates and the
concentration of plasma MDA was expressed in µmol/l.
MDA standards (1.25, 2.5, 5, 8 and 10 µmol/l) were
prepared from acid hydrolysis of 1,1,3,3-tetraethoxypropane
(TEP) according to the method of Tsaknis and co-workers
with modifications [39].
Other measurements
Glucose levels were measured by using the hexokinase-
glucose-6-phosphate dehydrogenase UV-method of Kunst et
al. [40]. HDL cholesterol, triglyceride and total cholesterol
levels were measured by enzymatic methods using Dimension
Clinical Chemistry System (Dade Behring Inc., Newark, DE).
LDL cholesterol was calculated with the Friedewald formula
[41]. Percent HbA1c was determined by COBAS INTEGRA
systems (Roche diagnostics, F. Hoffmann-La Roche Ltd, Basel,
Switzerland) according to the manufacturer’s instructions.
Statistical analysis
Data are expressed as the mean ± standard deviation
(SD). Chi-square (X2) test was used for the analysis of
categorical variables. Differences among the fuor groups
(Type 2 diabetes with IHD, IHD without Type 2 diabetes,
Type 2 diabetes without IHD, and healthy control subjects)
were examined by one-way analysis of variance (ANOVA).
If analysis of variance indicated that p<0.05, Bonferroni’s
Post Hoc test was applied to adjust the multiple comparisons.
Coefficients of correlation of CML with other parameters of
Type 2 diabetes including serum glucose, diabetes duration,
LDL-cholesterol, and MDA were calculated using Pearson’s
correlation analysis. Statistical computations were calculated
using SPSS 11.5 for Windows software (SPSS Inc, Chicago,
IL).
Results
Characterization of CML- and CEL-modified proteins
Agarose gel electrophoresis was used to evaluate the
purity of the modified proteins employing 1.5% agarose in
Tris-glycine buffer. Figure 1 showed that CML- and CEL-
glycated proteins preparations revealed a faster anodic
migration than native BSA or Hb, indicating that significant
glycation had occurred. Quantitatively, the modified proteins
were subjected to TNBS assay to estimate the amount of
glycation. The degree of glycation was calculated from the
reduction of absorbance compared with native proteins and
expressed as percentage of modification. The percentages of
lysine residues modifications in CML-BSA, CEL-BSA,
CML-Hb, and CEL-Hb CML- and CEL-glycated proteins
versus total lysine residues in the native proteins are 66, 48,
62, and 39%, respectively.
Preparation of polyclonal anti-CML antibodies and charac-
terization by ELISA
To develop an antiserum that would selectively and
specifically recognize CML adducts, but not epitopes of
native proteins, the rabbit was immunized with CML-BSA.
The anti-CML-BSA titer was determined to be greater
than 36000 in a non-competitive ELISA. The specificity of
the antiserum was tested by a competitive ELISA and results
are shown in Fig. 2. CML-BSA and CML-Hb were highly
effective competitors and significantly reacted with anti-CML
Fig. 1.  Agarose gel electrophoresis of glycated and nonglycated
proteins. Native BSA (lane 1), CML-BSA (lane 2),
CEL-BSA (lane 3), CEL-Hb (lane 4), CML-Hb (lane 5)
and Hb (lane 6). Samples in loading buffer (bromophenol
blue, 1.5 M Tris and 20% glycerol, pH 9.2) were loaded
into agarose gel (1.5%) in 0.1 M Tris and 0.038 M
glycine buffer (pH 8.7). The gel tray was run for 40–
60 min at 100 V. The gel was stained with 1% Coomassie
blue (1 h) followed by overnight destaining.CML and Ischemic Heart Disease in Type 2 Diabetes
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antibodies, whereas the native (BSA, Hb) and CEL-modified
proteins (CEL-BSA, CEL-Hb) were not recognized by the
antibody. Thus, this monospecific antiserum is specifically
directed to the CML epitope, able to recognize it on any of a
variety of different proteins.
Clinical characteristics of study populations
Table 1 shows the clinical characteristics of the study
groups. The study populations were well matched for age and
gender with their respective control groups. The mean ages
in these groups, healthy control subjects, Type 2 diabetes
patients with IHD, IHD patients without Type 2 diabetes, and
Type 2 diabetics without IHD were 44.0 ± 14.0, 43.7 ± 14.9,
48.4 ± 18.1, and 45.2 ± 17.1 years respectively and the
age difference between these groups was not significant
(p = 0.48). The four groups were comparable with respect
to gender as tested by Chi-square (p = 0.56). When the
four groups were compared, a statistical significance was
observed in the levels of serum fasting blood glucose, lipids
(triglyceride, total cholesterol, HDL-cholesterol), MDA,
HbA1c and CML, and to a lesser extent in LDL-cholesterol.
Fig. 3 shows that CML levels were markedly higher in
diabetics with IHD when compared to other groups of the
study. There was no significant difference in systolic blood
pressure and diastolic blood pressure among the study
groups. For all variables in the study groups that showed
statistical significance by analysis of variance, post-hoc
comparisons of means were made using the Bonferroni test.
Clinical parameters were also compared between diabetic
patients (Type 2 diabetes with and without IHD) groups. The
durations of diabetes in the Type 2 diabetics with IHD and
without IHD were 9.3 ± 4.0 and 9.9 ± 5.0 years respectively.
Fig. 2.  Immunoreactivity of the polyclonal anti-CML antibody
to CML-proteins. The immunoreactivity of the polyclonal
anti-CML antiserum was determined by competitive
ELISA. The microplate wells were coated with 100 µl of
CML-BSA (1.0 µg/ml) in 50 mM carbonate buffer
(pH 9.6) at room temperature for 1 h. Wells were washed
three times with buffer A and blocked with 6% skimmed
milk for 1 h followed by triple washing. Each protein or
competitor to be tested with different concentrations
(60 µl) was mixed with equal volume of antiserum (final
dilution 1:2000) for 1 h and a portion (100 µl) of the
mixture was then added to the wells followed by incubation
for 1 h. After triple washing, HRP-conjugated anti-rabbit
IgG antibody (0.1 µg/ml) was used to detect the antibodies
bound to wells as described in the methods section.
Table 1. Clinical and laboratory characteristics of the study groups
Healthy 
controls
Diabetes 
with IHD
IHD without 
diabetes
Diabetes 
without IHD
p value*
Sex (Male/Female) 80 (36/44) 60 (32/28) 43 (22/21) 64 (29/35) NS
Age (years) 44.0 ± 14.0 43.7 ± 14.9 48.4 ± 18.1 45.2 ± 17.1 NS
Systolic blood pressure (mmHg) 123.8 ± 18.1 131.5 ± 19.8 125.4 ± 21.1 123.6 ± 19.8 NS
Diastolic blood pressure (mmHg) 77.6 ± 9.5 77.8 ± 8.0 78.4 ± 7.6 77.4 ± 7.7 NS
Fasting blood glucose (mmol/l) 4.94 ± 0.74 7.88 ± 3.23 5.25 ± 0.96 7.02 ± 2.09 <0.001
HbA1c (%) 5.80 ± 0.69 7.00 ± 1.28 6.06 ± 0.96 6.58 ± 1.50 <0.001
CML (ng/ml)  416.6 ± 71.5 537.1 ± 86.1** 410.0 ± 76.3 449.7 ± 54.9 <0.001
MDA (µmol/l) 1.80 ± 0.50 2.73 ± 1.01** 2.19 ± 0.65 2.21 ± 0.72 <0.001
Triglyceride (mmol/l) 1.34 ± 0.83 1.81 ± 1.23 1.23 ± 0.57 1.28 ± 0.75 0.002
Total cholesterol (mmol/l)† 5.42 ± 0.86 4.81 ± 0.89 5.06 ± 1.00 5.02 ± 0.87 0.001
HDL-Cholesterol (mmol/l)† 1.24 ± 0.38 0.99 ± 0.34 1.05 ± 0.36 1.06 ± 0.37 <0.001
LDL-Cholesterol (mmol/l)† 3.58 ± 0.76 3.14 ± 0.84 3.45 ± 0.98 3.42 ± 0.86 0.028
ANOVA followed by Bonferroni-corrected repeated pair comparisons were used for statistical analysis; values are mean ± SD. *Significantly
different between groups if p<0.05. NS; the difference is not significant. **p<0.005 vs Diabetes without IHD, IHD without diabetes, and
Healthy subjects. †Lower values in patients than healthy controls due to using lipid-lowering drugs.K.A. Ahmed et al.
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Although triglyceride levels were significantly higher in
Type 2 diabetes patients with IHD than diabetics without
IHD (p = 0.007), all lipid profiles including total cholesterol,
HDL-cholesterol and LDL-cholesterol were not significant.
The difference in the fasting blood glucose levels was not
significant between diabetic patients groups. However, patients
with Type 2 diabetes and IHD had significantly higher levels
of MDA and CML levels than diabetic patients without
IHD; 2.73 ± 1.01 vs 2.21 ± 0.72, p = 0.001 and 537.1 ± 86.1
vs 449.7 ± 54.9, p<0.001, respectively (Table 1). Correlation
studies showed that serum CML levels in Type 2 diabetes
with IHD were positively and significantly correlated with
MDA (r = 0.338, p = 0.008) (Fig. 4A) and such correlations
were not found between the serum levels of CML and age
(r = 0.168, p = 0.19), HbA1c (r = 0.067, p = 0.61) and LDL-
cholesterol (r =− 0.097, p = 0.46). However, MDA was not
correlated with the CML concentrations in Type 2 diabetes
but without IHD (r = 0.035, p = 0.78) (Fig. 4B).
Discussion
It is well established that diabetes is a serious and costly
disease that is becoming increasingly common in many
countries and the level of mortality and morbidity from
coronary heart disease is higher in diabetic patients than
nondiabetic individuals [42]. Furthermore, it is well known
that diabetes is associated with silent ischemia [43, 44]. This
fact should be taken into account to develop a suitable
determinant for the early detection of these complications
and subsequently reduce the adverse effect of diabetes.
Indeed, it is critical that the focus of the development of new
markers targeting the prediction and early detection of
macrovascular complications, specifically IHD, in Type 2
diabetes remains an important research and clinical objectives.
Investigations have shown that serum AGEs concentrations
were observed in Type 2 diabetes with coronary artery disease
[45, 46] but these studies failed to show the importance of
the glycoxidation product, Nε-(carboxymethyl)lysine, in the
development of heart diseases in the respective groups of the
studies. In fact, the data regarding the importance of CML in
the development of IHD in patients with diabetes are scarce
so far.
The results of this study demonstrates that both CML and
MDA were significantly elevated in Type 2 diabetes mellitus
accompanied with ischemic heart disease when compared to
Fig. 3. Concentrations  of  Nε-(carboxymethy)lysine (CML) in the
study groups. Data represent means ± SD. **p<0.001
versus healthy controls, IHD patients without Type 2
diabetes, and Type 2 diabetics without IHD.
Fig. 4.  Correlation between CML and MDA in the two diabetic groups. CML levels were significantly correlated with MDA
(r = 0.338, p = 0.008) in diabetic IHD patients (A) but not in Type 2 diabetes patients without IHD (B) (r = 0.035, p = 0.78)).CML and Ischemic Heart Disease in Type 2 Diabetes
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that of Type 2 diabetes mellitus without IHD, healthy control
subjects, or IHD patients without diabetes. Furthermore,
MDA levels showed that the significant difference between
means in age- and sex-matched healthy control subjects and
nondiabetic IHD patients (p = 0.035) was seen but to a much
lesser extent in comparison of the Type 2 diabetes with IHD
group with either healthy individuals, diabetics without IHD,
or nondiabetic IHD patients. The findings reported in this
study explain that this slight increase in MDA concentrations
in the patients with IHD alone may be derived from oxidative
stress, imbalance between antioxidants defence mechanisms
and oxidants, rather than carbohydrates or hyperglycemia.
Our results are in a good agreement with the previous
investigation that formation of MDA on LDL, an end
product of lipid peroxidation, may indicate that the circulating
MDA-LDL level is increased in coronary artery disease
(CAD) compared with the levels in the patients without
CAD [47].
Recently, it has been shown that CML may be formed by
the copper-ion catalyzed oxidation of LDL in presence of
glucose and CML was not detected in LDL incubated
with copper ion alone indicating the synergetic effect of
glucose on lipid peroxidation and subsequently accumulation
of glycoxidized LDL in the macrophage- derived foam cells
[48].
Bivariate correlation studies show that CML levels in
Type 2 diabetic patients with IHD were positively and
significantly affected by MDA levels and these correlations
were not seen in Type 2 diabetes patients without IHD,
indicating that the extent of LDL-cholesterol oxidation plays
a crucial role in the formation and subsequent increase in
CML levels in Type 2 diabetes accompanied by macro-
vascular complications including IHD. With regard to lipids
and lipoproteins, it has been demonstrated that the lack
relationship between CML and LDL-cholesterol and other
lipid profile (data not shown) was observed among diabetics.
The main reason for these unusual findings is that most of
these patients are on lipid-lowering drugs. Since it has been
established that CML levels are increased in the serum with
aging [36], our findings exclude the effect of age on CML
levels in Type 2 diabetic patients with IHD as explained by
correlation analysis (r = 0.05, p = 0.69).
In conclusion, our study showed a significant association
between serum CML levels and Type 2 diabetic complications,
especially ischemic heart disease. These findings reported
in the present study show that raised CML levels reflect
the enhanced oxidative stress due to higher blood glucose
levels in diabetic IHD patients and may be used as a useful
independent biomarker for the ischemic heart disease
resulting from Type 2 diabetes mellitus.
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